Pacira BioSciences, Inc.PCRXEarnings & Financial Report
Nasdaq
PCRX Q3 2025 Key Financial Metrics
Revenue
$179.5M
Gross Profit
$145.2M
Operating Profit
$6.4M
Net Profit
$5.4M
Gross Margin
80.9%
Operating Margin
3.5%
Net Margin
3.0%
YoY Growth
6.5%
EPS
$0.12
Financial Flow
Pacira BioSciences, Inc. Q3 2025 Financial Summary
Pacira BioSciences, Inc. reported revenue of $179.5M for Q3 2025, with a net profit of $5.4M (3.0% margin). Cost of goods sold was $34.3M, operating expenses totaled $138.9M.
Key Financial Metrics
| Total Revenue | $179.5M |
|---|---|
| Net Profit | $5.4M |
| Gross Margin | 80.9% |
| Operating Margin | 3.5% |
| Report Period | Q3 2025 |
Pacira BioSciences, Inc. Annual Revenue by Year
Pacira BioSciences, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $675.0M).
| Year | Annual Revenue |
|---|---|
| 2023 | $675.0M |
| 2022 | $666.8M |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $163.9M | $181.2M | $167.1M | $178.0M | $168.6M | $168.9M | $181.1M | $179.5M |
| YoY Growth | -2.1% | 5.4% | 4.2% | 5.0% | 2.8% | 1.1% | 1.7% | 6.5% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.53B | $1.57B | $1.58B | $1.65B | $1.52B | $1.59B | $1.54B | $1.30B |
| Liabilities | $702.9M | $704.3M | $691.2M | $767.5M | $772.1M | $788.1M | $779.5M | $570.4M |
| Equity | $831.6M | $870.1M | $892.2M | $879.3M | $749.6M | $798.5M | $757.8M | $727.2M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $44.4M | $47.6M | $49.1M | $53.2M | $53.9M | $35.5M | $12.0M | $60.8M |